Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter Caravan
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Collagen Medical, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Collagen Medical, LLC is developing targeted MRI contrast agents to diagnose and stage fibrotic disease and assess response to therapeutic interventions. The research project develops a novel thrombus body scan (TBS) for VTE diagnosis using a new fibrin-specific probe for PET imaging and involves a peptide which is licensed to Collagen Medical. The results of this study could therefore be of interest to the company. The Partners Committee on Outside Activities review panel evaluated the financial interest in connection with this research project and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
PET fibrin imaging of DVT and PE
PROJECT NARRATIVE Venous thromboembolism (VTE) is one of the most common causes of death in the United States, resulting in more than 100,000 deaths annually. Current diagnostic techniques rely on indirect measures of clot for diagnosis and therefore suffer from the problems of both under and overdiagnosis and cannot always be performed on patients with renal failure and lung disease. This project will address this major health problem by evaluating a new fibrin-specific targeted non-invasive imaging technique for VTE.
Filed on May 04, 2018.
Tell us what you know about Peter Caravan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Peter Caravan”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Collagen Medical, LLC | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Factor 1A, LLC | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Brigham and Women's Hospital | Conflict of Interest | Catalyst Medical | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Brigham and Women's Hospital | Conflict of Interest | Collagen Medical | $10,000 - $19,999 |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Factor 1A, LLC | Value cannot be readily determined |
| Peter Caravan | Brigham and Women's Hospital | Conflict of Interest | Factor 1A, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.